PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced that the PINNACLE I study evaluating the safety and ...
The MarketWatch News Department was not involved in the creation of this content. --Primary safety and effectiveness endpoints were met with 98% clinical success rate and 100% angiographic success in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results